U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07446582) titled 'Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection' on Feb. 23.
Brief Summary: The goal of this observational clinical study is to learn if DeepMSI AI detects age-related macular degeneration (AMD) biomarkers with sensitivity and specificity equivalent to experienced clinicians in adults over 40 years old. The main questions it aims to answer are:
* Does DeepMSI AI detect AMD biomarkers with sensitivity equivalent to experienced clinicians?
* Does DeepMSI AI detect AMD biomarkers with specificity equivalent to experienced clinicians? Participants' eyes will be imaged by MSI-120 and their i...